A report on the sponsors of cancer treatment clinical trials and their approval and monitoring mechanisms

This report for the National Cancer Policy Board (NCPB) describes the procedures currently in place in the United States for approving and monitoring clinical trials of cancer treatments. Virtually all cancer clinical trials are funded by agencies of the federal government or the pharmaceutical indu...

Full description

Bibliographic Details
Main Author: Gelband, Hellen
Corporate Author: National Cancer Policy Board (U.S.)
Format: eBook
Language:English
Published: Washington D.C. National Research Council 1999, 1999
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01890nam a2200265 u 4500
001 EB002000224
003 EBX01000000000000001163125
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
100 1 |a Gelband, Hellen 
245 0 0 |a A report on the sponsors of cancer treatment clinical trials and their approval and monitoring mechanisms  |h Elektronische Ressource  |c Hellen Gelband ; prepared for the National Cancer Policy Board 
260 |a Washington D.C.  |b National Research Council  |c 1999, 1999 
505 0 |a Includes bibliographical references 
653 |a Neoplasms / therapy / https://id.nlm.nih.gov/mesh/D009369Q000628 
653 |a United States / https://id.nlm.nih.gov/mesh/D014481 
653 |a Clinical Trials as Topic / standards / https://id.nlm.nih.gov/mesh/D002986Q000592 
710 2 |a National Cancer Policy Board (U.S.) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
500 |a Title from caption (viewed June 14, 2001). - "February 1999.". - Mode of access: Internet 
856 4 0 |u http://www.nap.edu/catalog.php?record_id=9442  |3 Volltext  |n Provider site  |3 Volltext 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK224011  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a This report for the National Cancer Policy Board (NCPB) describes the procedures currently in place in the United States for approving and monitoring clinical trials of cancer treatments. Virtually all cancer clinical trials are funded by agencies of the federal government or the pharmaceutical industry, so the focus is on the requirements for each of these groups. The paper is intended as a jumping off point for the NCPB to consider some of the pressing policy issues surrounding clinical trials in cancer, though as yet, no specific follow-on projects have been initiated